RUSSELL WILKE

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy
    R A Wilke
    Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Clin Pharmacol Ther 92:112-7. 2012
  2. ncbi Mapping genes that predict treatment outcome in admixed populations
    T M Baye
    Division of Asthma Research, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229 3039, USA
    Pharmacogenomics J 10:465-77. 2010
  3. ncbi High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome
    R A Wilke
    Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA
    Pharmacogenomics J 11:162-73. 2011
  4. ncbi The emerging role of electronic medical records in pharmacogenomics
    R A Wilke
    Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Clin Pharmacol Ther 89:379-86. 2011

Research Grants

  1. Pharmacogenetics of obesity and endocannabinergic modulation (POEM)
    Russell A Wilke; Fiscal Year: 2010
  2. Pharmacogenetics of obesity and endocannabinergic modulation (POEM)
    Russell A Wilke; Fiscal Year: 2009

Detail Information

Publications4

  1. ncbi The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy
    R A Wilke
    Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Clin Pharmacol Ther 92:112-7. 2012
    ..This guideline explores the relationship between rs4149056 (c.521T>C, p.V174A) and clinical outcome for all statins. The strength of the evidence is high for myopathy with simvastatin. We limit our recommendations accordingly...
  2. ncbi Mapping genes that predict treatment outcome in admixed populations
    T M Baye
    Division of Asthma Research, Department of Pediatrics, Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, OH 45229 3039, USA
    Pharmacogenomics J 10:465-77. 2010
    ....
  3. ncbi High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome
    R A Wilke
    Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA
    Pharmacogenomics J 11:162-73. 2011
    ..As these biobanks combine resources, the clinical community is in a position to characterize lipid-related treatment outcome on an unprecedented scale...
  4. ncbi The emerging role of electronic medical records in pharmacogenomics
    R A Wilke
    Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Clin Pharmacol Ther 89:379-86. 2011
    ..This review explores each of these translational mechanisms within a historical framework...

Research Grants3

  1. Pharmacogenetics of obesity and endocannabinergic modulation (POEM)
    Russell A Wilke; Fiscal Year: 2010
    ..In the future, individual patients with variation in these genes may benefit from targeted behavioral and/or pharmacological interventions designed to improve their health. ..
  2. Pharmacogenetics of obesity and endocannabinergic modulation (POEM)
    Russell A Wilke; Fiscal Year: 2009
    ..In the future, individual patients with variation in these genes may benefit from targeted behavioral and/or pharmacological interventions designed to improve their health. ..